ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
April 06 2022 - 6:32AM
Business Wire
Tru Niagen® Immune
is the first-ever immune health supplement with a targeted NAD+
boost for the optimal maintenance and function of aging cells
ChromaDex Corp. (NASDAQ:CDXC) today announced the company’s
latest product innovation with the U.S. launch of Tru Niagen®
Immune, a first-of-its-kind combination of ChromaDex’s proprietary
NAD-boosting ingredient Niagen® (patented nicotinamide riboside or
NR), high-quality and proven immune-boosting nutrients (vitamins C,
D, and zinc) for the optimal maintenance of aging cells, and
Theracurmin® (a superior form of curcumin). NAD+ is important to
the healthy function of immune cells and is depleted by up to 80%
when the body is under immune stress. Born from consumer insights,
this new innovation was created to fulfill a customer need for an
immune product. Tru Niagen Immune is now available online in the
United States.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220406005154/en/
ChromaDex Launches New Product
Innovation: Tru Niagen® Immune (Photo: Business Wire)
“Our community asked for a holistic daily immune supplement, and
we listened to what they had to say. Tru Niagen Immune features an
all-in-one formula with best-in-class and scientifically supported
ingredients that work together,” said Rob Fried, CEO of ChromaDex.
“Our team of scientists were meticulous and strategic in creating
this formula to ensure high bioavailability and efficacy of the
ingredients. We are thrilled to give our community what they want
with this new launch.”
Although the initial recommended daily serving of Niagen is
300mg, the majority of clinical studies conducted through the
ChromaDex External Research Program (CERP™) use 1,000mg or more of
Niagen. Research has shown that taking higher doses of Niagen
further increases NAD+ levels, which may benefit overall cellular
health and immune cell health. Tru Niagen Immune is intended to be
a companion to Tru Niagen, and it is recommended that both products
be taken together for additional NAD+ support.
“Research shows the Standard American Diet falls short of the
recommended intake of fruit, vegetables, lean protein, and whole
grains, which provide key immune-supporting nutrients such as
vitamins C, D and zinc,” said Mona Rosene, MS, RD, and ChromaDex
Director of Scientific Affairs. “Instead, we often consume foods
high in saturated fat, salt and added sugar. This was a key factor
in how we approached the formulation of Tru Niagen Immune. We
wanted to develop a product that provides these important
nutrients; therefore, we combined the proven immune-boosting
nutrients vitamins C, D, and zinc with our proprietary Niagen
ingredient, which increases vital cellular NAD+ levels, and a
highly absorbable form of curcumin.”
Tru Niagen Immune features high-quality ingredient sources with
supreme efficacy. Combining the cellular defense and repair power
of Niagen with proven immune-boosting nutrients, Tru Niagen Immune
offers a best-in-class formulation:
- 150mg of Niagen® (nicotinamide riboside or NR) to further boost
NAD+
- 2,000IU (250% daily value) of VegD3® a proprietary form of
plant-based vitamin D3 derived from algae, as opposed to
animal-sourced lanolin
- 20mg (182% daily value) of zinc in two forms, gluconate and
citrate, for better absorption
- 180mg (200% daily value) of vitamin C produced via
fermentation, as opposed to synthetically sourced
- 30mg Theracurmin®, a superior form of curcumin that is 27x more
absorbable than regular curcumin
“I have been taking individual immune supplements for years and
was thrilled to hear that the Tru Niagen team created a holistic,
high-quality supplement that both increases NAD+ levels and
supports immune health,” said Brooke Burke, fitness expert,
entrepreneur, and Tru Niagen ambassador. “Tru Niagen and Tru Niagen
Immune are life-changing and I believe that if you’re going to take
any supplement, this routine should be number one.”
Tru Niagen Immune is available in a 30-count bottle for $37.50
on www.truniagen.com and www.amazon.com.
For additional information on the science supporting Niagen
visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related whether Tru Niagen Immune
will fulfill a customer need for an immune product. Statements that
are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects," "anticipates,"
"intends," "estimates," "plans," "potential," "possible,"
"probable," "believes," "seeks," "may," "will," "should," "could"
or the negative of such terms or other similar expressions. Other
risks that contribute to the uncertain nature of the
forward-looking statements include: unfavorable publicity or
changing consumer perceptions of our products; our inability to
commercialize further products; reliance on a single or limited
number of third-party suppliers for raw materials to produce our
products; and the risks and uncertainties associated with our
business and financial condition in general, described in
ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220406005154/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024